Last reviewed · How we verify
NCT06937996
Outcomes of Ablation of Unresectable Pancreatic Cancer Using the NanoKnife Irreversible Electroporation System-
trial testing NanoKnife in Pancreatic Cancer Non-resectable in 25 participants. Currently enrolling.
31 May 2035
Quick facts
| Lead sponsor | Englewood Hospital and Medical Center |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 25 |
| Start date | 13 May 2025 |
| Primary completion | 31 May 2035 |
| Estimated completion | 31 May 2035 |
| Sites | 1 location across United States |
Drugs / interventions tested
- NanoKnife
Conditions studied
- Pancreatic Cancer Non-resectable — all drugs for Pancreatic Cancer Non-resectable →
Sponsor
Englewood Hospital and Medical Center
Who can join
18 and older, any sex, with Pancreatic Cancer Non-resectable. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to evaluate the short and intermediate term safety of the NanoKnife Irreversible Electroporation System when used off-label to treat unresectable pancreatic cancer. In addition, the study will evaluate the efficacy of this device in treating pain associated with unresectable pancreatic cancer. Quality of life post-procedure will also be collected.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06937996
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of NanoKnife
Trials testing the same drug.
- NCT02430675 — Irreversible Electroporation(IRE) For Unresectable Laryngeal Neoplasms · NA · completed
- NCT02430597 — Irreversible Electroporation(IRE) For Unresectable Hilus Pulmonis Neoplasms · NA · completed
- NCT02430779 — Irreversible Electroporation(IRE) For Unresectable Renal Pelvic and Ureteral Neoplasms · NA · completed
- NCT02335112 — Irreversible Electroporation(IRE) For Unresectable Head and Neck Neoplasms · NA · completed
- NCT02430662 — Irreversible Electroporation(IRE) For Unresectable Gallbladder Neoplasms · NA · completed
Other recruiting trials for Pancreatic Cancer Non-resectable
Currently open trials in the same condition.
- NCT07326150 — Construction of a Predictive Model for the Efficacy of Chemoprevention Combined With Targeted Therapy in Pancreatic Canc · active not recruiting
- NCT07066995 — Mesothelin and Claudin 18.2 Dual-Target CAR-T Therapy in Advanced Pancreatic Cancer · Phase 1, PHASE2 · recruiting
- NCT06840067 — Clinical Study of Carbon Ion Radiotherapy for Pancreatic Cancer. · NA · recruiting
- NCT07271823 — Establishment of a Predictive Model for Immunotherapy Response in Pancreatic Cancer · active not recruiting
- NCT06503497 — A Trail of Second-line Chemotherapy Sequential NKG2D CAR-NK Cell Therapy for Pancreatic Cancer · EARLY_PHASE1 · recruiting
Other Englewood Hospital and Medical Center trials
Trials by the same sponsor.
- NCT06681818 — Novel Method to Assess Hepatic Regeneration and Predict Hepatic Related Morbidity After Partial Hepatectomy · NA · recruiting
- NCT06970925 — Pilot Study Evaluating the Advantages of Sucrosomial® Iron Post-operative Supplementation vs Standard of Care After Card · EARLY_PHASE1 · recruiting
- NCT05193643 — Minimally Invasive Treatment of Primary Great Saphenous Vein (GSV) Insufficiency Using High Intensity Focused Ultrasound · NA · completed
- NCT04124783 — Study to Evaluate the Effects of the Cooling Bolero in Women With Menopause Symptoms · NA · withdrawn
- NCT04116697 — A Randomized Controlled Trial to Evaluate the Efficacy of Acupuncture Versus Aromatherapy as Treatments to Lessen Nausea · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06937996 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Englewood Hospital and Medical Center
- Last refreshed: 17 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06937996.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing